Central Fax: 403-955-8634 (referrals)
The Division of Endocrinology and Metabolism at the University of Calgary has a group of physicians dedicated to providing the highest standard of care for patients diagnosed with Thyroid Cancer. Our physicians are highly trained clinically and are world renowned researchers in Thyroid Cancer. We work closely with our colleagues in Head and Neck surgery, Endocrine surgery, Pathology, Diagnostic Imaging and Radiation & Medical Oncology, to discuss cases and to ensure our patients are getting the most up to date and individualized care possible.
Our mission is to provide comprehensive, timely and personalized treatment to patients, provide regional and international leadership in the care of thyroid cancer patients through the development of guidelines and standards of care, outcomes evaluations, and clinical investigations.
Physician referrals to the Endocrinology Division for thyroid cancer can be made by filling in the generic referral form and faxing it to our central access and triage.
Our patients with a diagnosis of thyroid cancer are seen at several sites including the Tom Baker Cancer Center, Richmond Road Diagnostic and Treatment Center (RRDTC) and the Associate Clinic. We are currently working towards centralizing our appointments at RRDTC to provide a multi-disciplinary thyroid cancer clinic.
Thyroid Cancer Tumor Group
- All new referrals with a new diagnosis of thyroid cancer are triaged and discussed weekly by our thyroid cancer endocrinologists to ensure patients are prioritized for evaluation. Tentative and standardized care plans are made for consideration of adjuvant therapy with radioiodine and the involvement of colleagues from other disciplines.
- Our team of physicians involved in thyroid cancer management meet each month at Thyroid Cancer Tumor Board Rounds. These are evidence-based, multispecialty (Endocrinology, Head and Neck surgery, Endocrine surgery, Pathology, Diagnostic Imaging and Radiation & Medical Oncology) presentations that evaluate and discuss the best treatment options based on each patient’s diagnosis and specific medical needs. Clinical trial therapies are considered as part of treatment planning when appropriate for each case. These rounds provide an excellent opportunity for our team to collaborate and remain up to date on the most current evidence and, as a result, provide patients with optimal care plans to achieve the best possible outcomes.
- We have developed recent protocols to meet the evolving changes in the diagnosis and treatment of thyroid cancer aiming to develop an individualized and personalized plan for each patient based upon the estimated risk of cancer recurrence. The extent of surgery (total thyroidectomy vs. lobectomy), the need for radioiodine treatment and the option for active surveillance for very small thyroid cancers are debated on each patient based upon the best evidence gleaned from the rapidly evolving medical literature and current guidelines.
- Through research and scholarly work, we are in the process of evaluating our population in Southern Alberta to establish the risk of malignancy based upon ultrasonographic criteria and categories of results obtained from fine needle aspiration biopsies of thyroid nodules. Indeterminate biopsy results remain challenging so molecular testing of fine needle aspiration biopsy samples is a major focus of our research. We are optimistic that through appropriate mutation testing we may be able to reduce the number of diagnostic thyroid surgeries by 80% leading to significantly lower patient morbidity and anxiety plus substantial cost savings.